Corporate Presentation

April 2016 1NASDAQ: CYRX

This presentation contains certain forward-looking statements that involve risks and

uncertainties. Such forward-looking statements include statements regarding attempts to

identify new strategic opportunities which may include a strategic transaction, plans

regarding partnering activities, product pricing, financial forecasts. Such statements are

only predictions and the Company's actual results may differ materially from those

anticipated in these forward-looking statements. Factors that may cause such differences

include the risk that the Company may not be able to identify acceptable strategic

opportunities or conclude any strategic transaction which it does identify, the risk that

products that appeared promising in early use do not demonstrate the same utility in

larger-scale uses, the risks associated with the Company's reliance on outside financing to

meet its capital requirements, and the risks associated with the Company's reliance on

collaborative partners for shipping. Forward-looking statements are inherently subject to

risks and uncertainties, some of which cannot be predicted, or quantified. Future events

and actual results could differ materially from those set forth in, contemplated by, or

underlying the forward-looking statements. The risks and uncertainties to which forward-

looking statements are subject include, but are not limited to, the effect of government

regulation, competition and other material risks. These factors and others are more fully

discussed in the Company's periodic reports and other filings with the Securities and

Exchange Commission.

safe harbor – forward looking statements

April 2016 2

vision

to be the most comprehensive, fully integrated,

commercially successful life sciences enabling company in

the world providing full support including logistics, storage,

information for science and regulatory compliance and

fulfillment

to be known for leadership and dependability

to be known for agility, reliability, innovation, and

excellence

April 2016 3

company highlights

undisputed leading provider of advanced cryogenic logistics solutions for

the life sciences industry, an addressable market of over $2.0 billion*

growing more than 14% per year

fully integrated with FedEx, DHL and UPS

Q3 FY 2016 revenue increased 58%

over 28,000 shipments through 90 countries

over 550 clients engage our solutions today; 98 new biopharma clients

were added during the first three quarters

supporting 64 clinical trials with 10 in Phase III, which represents

approximately 20% of all the Phase III clinical trials for regenerative

therapies – including 8 of the top 10 CAR T-cell therapies

*Cryoport estimate for 2015

April 2016 4

life sciences cryogenic logistics market

could

should

current

temperature

+2 to +8˚C

- 80˚C

- 150˚C

dry ice

cryogenic

secondary market($300M – $500M)**

primary market

(approx. $1.7B)**

cry

op

ort

al

so

ftw

are

cry

op

ort

sh

ipp

ers

glass point

total life sciences cold chain logistics

services

(approx. $10B)*

*iMarc Report Global Healthcare Cold Chain Logistics Market Report & Forecast (2012-

2017); extrapolated for 2015

**Cryoport estimate for 2015

solutions

April 2016 5

biopharma/regenerative medicine

Source: Alliance for Regenerative Medicine, January 2016

6April 2016 6

biopharma market

The total biologics market is estimated to be $289 billion today and

growing at 10.8% annually; by extrapolation, in 2025 the market will be an

$800 to $900 billion, which will accelerate the cryogenic market growth

April 2016 7

cryoport express® shippersvalidated. safe. effective. efficent.

Cryoport

Express

®

Shipper

novel liquid nitrogen dry vapor technologies

(lighter than LN2 and dry ice)

designed for fragile biologic transport

stable cryogenic temperature below -150˚C

(below the “glass point”)

10 day “dynamic” holding time without need

for intervention

international air transport association (IATA)

certified, non-hazardous and “green”

smart pak® condition monitoring system

which monitors internal and external

temperatures, humidity, openings, etc

April 2016 8

proprietary information technology

the cryoportalTM is a cloud-based operating

platform that accepts orders, prepares paperwork,

tracks and monitors each shipment’s movement,

and maintains integrity throughout the entire

logistics process

vital information - dashboards and analytics for

visibility, analysis and improved operations

regulatory information - provides chain-of-custody and

chain-of-condition

innovative – carrier agnostic software developed for life

sciences cold chain with time and temperature

sensitivity

reliable – real time alerts and updates

cost effective – enables life sciences organizations to

manage their entire cold chain shipping process

April 2016 9

smart pak II® condition monitoring system chain-of-custody and chain-of-condition at your fingertips

10

real time tracking of key information – in beta testing

April 2016

global logistics expertise for life sciences

now serving over 90 countries, with recent expansion to Africa

global reach through cryoport’s operations centers in strategic locations

24/7/365 “live” logistics support

in compliance with regulations for the life sciences logistics space

enables customers to focus on their key competencies without the

concern of complicated logistics

Irvine, CA

11

strategic alliances:

April 2016 12

Renewed Dec 2015

CAR-T cell therapy logistics

demand is projected to ramp

significantly starting in late 2017,

2018

Cryoport is being requested to

support demand in the 100,000’s of

units a year required for a single

therapy (multiple examples).

Our data is consistent with this data

from GE, we project volumes in

excess of 1,000,000 by 2019

car t-cell immunotherapy – scale-out needs

April 2016 13

Source: Presentation by Clive Glover, GE Healthcare, May 2015

clinical trials supported by cryoport

44%

35%

21%

Clinical Trials by Phase

Phase I

Phase II

Phase III

0

10

20

30

40

50

60

Clinical Trials Initiated by Year and Cumulative

April 2016 14

15

revenue growth

April 2016

CAGR of 83% over last 3 years

broad customer base

+ 53% + 74%

+ 44%

+ 50%

board of directors & management

board of directors

Jerrell Shelton, Chairman/CEO

Richard Berman, Lead Director, Chairman of Audit and Compensation

Committees

Robert Hariri, PhD, MD, Director

Ramkumar Mandalam, Ph.D., Director

Edward Zecchini, Chairman of the Nominating and Governance Committee

management

Robert Stefanovich, Chief Financial Officer

Mark W. Sawicki, Ph.D., Chief Commercial Officer

Tamie Joeckel, Senior Vice President, Client Services

Bret Bollinger, Vice President Operations

Thomas Heinzen, Vice President Corporate Development

April 2016 16

strong market positioning

April 2016 17

growing $2.0B addressable market

over $150 million of embedded growth residing in current

trials supported

commitments from FedEx, UPS, and DHL to employ

“powered by cryoport”

increasing regulatory requirements

sustainable first-to-market advantage with array of

advanced logistics solutions

over 550 clients; including 98 new biopharma clients added

in first 3 quarters

advanced technology, reliable, easy, “green”,

patent-protected, and validated frozen shipping solutions

Science. Logistics. Certainty.

NASDAQ: CYRX 18